Eli Lilly and Company agreed to acquire Calytrix Bio, a biotechnology company developing precision therapies for myeloproliferative neoplasms. Calytrix shareholders could receive up to $1.5 billion in cash. The total includes an upfront payment and later clinical and regulatory milestone payments.
Funding history
Calytrix was founded in 2025 by J.P. Morgan Life Sciences Private Capital. It launched with a Series A financing co-led by J.P. Morgan Life Sciences Private Capital and Westlake BioPartners. A Series B financing followed, led by Avoro Ventures.
Company focus
Calytrix develops therapies for essential thrombocythemia and myelofibrosis. Current ET and MF drug treatments mainly manage symptoms and complications. The company is based in Wellesley Hills, Massachusetts.
Lead program
The lead asset is an investigational biparatopic antibody for disease driven by mutant calreticulin. It is designed to deliver pan-mutant activity against Type 1 and Type 2 mutant calreticulin. The company aims to offer a disease-modifying therapy with safety and convenience for early and long-term treatment.
Calytrix expects Lilly to advance the lead program through clinical development. Centerview Partners acted as exclusive financial advisor to Calytrix. Goodwin Procter served as legal counsel to Calytrix.